Merck's oral HIV treatment non-inferior to Gilead's Biktarvy in late-stage trial

Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...
Fierce Biotech

Merck's HIV combo matches Gilead's Biktarvy in latest phase 3 test for islatravir

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...

Merck HIV therapy matches Gilead’s Biktarvy in late-stage trial

Merck (MRK) announced on Wednesday that its single-tablet antiviral regimen, doravirine and islatravir for adults with HIV, ...
BioSpace

Gilead Looks To Simplify HIV Treatment By Combining Two Leading Drugs in One Pill

Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...
KFGO

Merck’s oral HIV treatment meets main goal in late-stage study

Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial. The company said ...

Merck's Investigational Two-Drug Regime Matches Gilead's Three-Drug Tablet For HIV Treatment

Merck's HIV pill met key efficacy and safety goals in Phase 3 trials, matching Biktarvy as the FDA reviews its application with a 2026 decision date.
Chemistry World

Crispr gene-editing technology offers new hope for HIV cure but faces delivery challenges

The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...

Early HIV drugs give immune system a brief reprieve before dysregulation returns, study finds

Despite effective HIV medication, the immune system of people with HIV remains disrupted in the long term.
Science Daily

Could this new hydrogel make HIV therapy more convenient?

The gel releases a steady dose of the anti-HIV drug lamivudine over six weeks, suggesting people living with HIV could have new therapy that doesn't require a daily pill regimen to prevent AIDS. A new ...